SANTA FE SPRINGS, Calif.– Applied BioCode announced today that Beth Laderman has been appointed as their new Chief Scientific Officer (CSO) signaling a significant step in the company’s expansion. With 25 years of experience in the medical diagnostic field, Dr. Laderman brings expertise from her previous roles at HYCOR Biomedical and Biomerica Inc. Her appointment is set to drive Applied BioCode’s focus on expanding its MDx-3000 platform and exploring new applications for its patented barcoded magnetic beads (BMBs). Dr. Laderman joins as Applied BioCode continues to expand its US commercial footprint and explores US & global expansion and new opportunities for their technology. With its current portfolio of PCR-based, multiplex molecular diagnostic assays in the respiratory and gastrointestinal markets, along with the new BioCode Fungal Panel RUO approval, the company remains steadfast in its mission in having R&D fully support the commercial enterprise by delivering transformative solutions for high-throughput diagnostics.
“I’m excited to be joining Applied BioCode and for the opportunity to support its mission to bring comprehensive, affordable, high throughput multiplex testing to all patients,” said Beth Laderman, incoming chief science officer for Applied BioCode. “I’m looking forward to using my passion for patients and broad experience to expand upon Applied BioCode’s innovative platform and technology.”
“I’m excited to welcome Beth to the leadership team as we sharpen our focus on expanding our MDx-3000 platform content and explore other applications for our patented barcoded magnetic beads (BMBs),” said Chris Bernard, chief executive officer of Applied BioCode. “Beth is a talented and innovative leader who has provided vision and led impactful change throughout her career. Her deep understanding of customer needs, the diagnostic market and the FDA process make her the perfect choice to help guide the next phases of our R&D journey.”
Dr. Laderman’s appointment as CSO of Applied BioCode marks an exciting chapter in the company’s journey to revolutionize diagnostics and life sciences. Her deep knowledge, leadership skills, and dedication to innovation are expected to drive the company’s research and development initiatives to new heights.
